Literature DB >> 15948093

NT-ProBNP reduction percentage during admission for acutely decompensated heart failure predicts long-term cardiovascular mortality.

Antoni Bayés-Genís1, Laura Lopez, Edgar Zapico, Carlos Cotes, Miquel Santaló, Jordi Ordonez-Llanos, Juan Cinca.   

Abstract

BACKGROUND: N-terminal brain natriuretic peptide (NT-proBNP) improves emergency room diagnosis of acutely decompensated heart failure. Less evidence is available on the usefulness of NT-proBNP as a prognostic marker after hospitalization for acute heart failure. The percentage of NT-proBNP reduction during admission and its prognostic significance were studied. METHODS AND
RESULTS: This was a prospective study of 74 patients in the emergency department who were diagnosed with acute heart failure and who had follow-up evaluation for 6 and 12 months after admission. Plasma NT-proBNP concentrations were measured on admission, at 24 hours, at day 7, and at 6 and 12 months. Eighteen patients died during the 12-month follow-up; 12 deaths were from cardiovascular causes. NT-proBNP concentrations were significantly higher in the emergency department and at 24 hours than those concentrations that were found at day 7 and beyond (P < .001). During admission, the NT-proBNP concentration fell a mean of 15% in patients who died of cardiovascular causes during the 1-year follow-up evaluation, in 75% in those patients who died of non-cardiovascular causes, and in 50% in survivors (P = .004). The area under the receiver operator characteristic curve for NT-proBNP reduction percentage to predict cardiovascular death was 0.78 (95% CI, 0.66-0.90; P = .002). A 30% NT-proBNP reduction percentage cutoff value had 75% accuracy for the identification of high-risk patients and was the only variable that was associated with cardiovascular death in multivariate analysis (odds ratio, 4.4; 95% CI, 1.12-17.4; P = .03).
CONCLUSION: NT-proBNP reduction percentage during admission for acutely decompensated heart failure appeared to be the best predictor of cardiovascular death during the follow-up period. A <30% NT-proBNP reduction percentage identified a subgroup of high-risk patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15948093     DOI: 10.1016/j.cardfail.2005.04.006

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  15 in total

Review 1.  BNP and NT-proBNP as prognostic markers in persons with acute decompensated heart failure: a systematic review.

Authors:  Pasqualina L Santaguida; Andrew C Don-Wauchope; Mark Oremus; Robert McKelvie; Usman Ali; Stephen A Hill; Cynthia Balion; Ronald A Booth; Judy A Brown; Amy Bustamam; Nazmul Sohel; Parminder Raina
Journal:  Heart Fail Rev       Date:  2014-08       Impact factor: 4.214

2.  Serial Measurement of Amino-Terminal Pro-B-Type Natriuretic Peptide Predicts Adverse Cardiovascular Outcome in Children With Primary Myocardial Dysfunction and Acute Decompensated Heart Failure.

Authors:  Shivanand Shankar Medar; Daphne T Hsu; H Michael Ushay; Jacqueline M Lamour; Hillel W Cohen; James S Killinger
Journal:  Pediatr Crit Care Med       Date:  2015-07       Impact factor: 3.624

3.  Admission, discharge, or change in B-type natriuretic peptide and long-term outcomes: data from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) linked to Medicare claims.

Authors:  Robb D Kociol; John R Horton; Gregg C Fonarow; Eric M Reyes; Linda K Shaw; Christopher M O'Connor; G Michael Felker; Adrian F Hernandez
Journal:  Circ Heart Fail       Date:  2011-07-08       Impact factor: 8.790

Review 4.  What Is New in Heart Failure Management in 2017? Update on ACC/AHA Heart Failure Guidelines.

Authors:  Biykem Bozkurt
Journal:  Curr Cardiol Rep       Date:  2018-04-17       Impact factor: 2.931

5.  Markers of decongestion, dyspnea relief, and clinical outcomes among patients hospitalized with acute heart failure.

Authors:  Robb D Kociol; Steven E McNulty; Adrian F Hernandez; Kerry L Lee; Margaret M Redfield; Russell P Tracy; Eugene Braunwald; Christopher M O'Connor; G Michael Felker
Journal:  Circ Heart Fail       Date:  2012-12-18       Impact factor: 8.790

6.  Clinical Research on Brain Natriuretic Peptide Guiding the Application of β1 Receptor Blocker in Patients with Moderate to Severe Heart Failure.

Authors:  Jiang-Jin Li; Xiao-Li Xiang; Xiao-Yi Tian; Ya-Fei Shi
Journal:  Acta Cardiol Sin       Date:  2015-01       Impact factor: 2.672

7.  In-hospital brain natriuretic peptide and N-terminal prohormone brain natriuretic peptide variations are predictors of short-term and long-term outcome in acute decompensated heart failure.

Authors:  Salvatore Di Somma; Laura Magrini; Enrico Ferri
Journal:  Crit Care       Date:  2011-02-01       Impact factor: 9.097

8.  Association of 25-hydroxyvitamin D deficiency with NT-pro BNP levels in patients with acute myocardial infarction: a cross-sectional analysis.

Authors:  James B Wetmore; Rajyalakshmi Gadi; John H Lee; James H O'Keefe; Paul S Chan; Fengming Tang; John A Spertus
Journal:  BMC Res Notes       Date:  2011-12-15

9.  Direct comparison of serial B-type natriuretic peptide and NT-proBNP levels for prediction of short- and long-term outcome in acute decompensated heart failure.

Authors:  Markus Noveanu; Tobias Breidthardt; Mihael Potocki; Tobias Reichlin; Raphael Twerenbold; Heiko Uthoff; Thenral Socrates; Nisha Arenja; Miriam Reiter; Julia Meissner; Corinna Heinisch; Sybille Stalder; Christian Mueller
Journal:  Crit Care       Date:  2011-01-05       Impact factor: 9.097

10.  Useulness of B Natriuretic Peptides and Procalcitonin in Emergency Medicine.

Authors:  S Delerme; C Chenevier-Gobeaux; B Doumenc; P Ray
Journal:  Biomark Insights       Date:  2008-03-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.